Novartis Ag Adr (NVS)

May 02, 2025

NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

May 02, 2025

May 02, 2025

Liver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research® - GlobeNewswire Inc.

May 02, 2025

Apr 29, 2025

Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar

Apr 29, 2025

Apr 29, 2025

Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com

Apr 29, 2025

Apr 29, 2025

Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar

Apr 29, 2025

Apr 29, 2025

Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com

Apr 29, 2025

Apr 22, 2025

Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail

Apr 22, 2025

Apr 21, 2025

Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? - Yahoo Finance

Apr 21, 2025

Apr 11, 2025

Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com

Apr 11, 2025

Apr 11, 2025

Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Newmont - WSJ

Apr 11, 2025

Apr 04, 2025

Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com

Apr 04, 2025

Apr 03, 2025

FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com

Apr 03, 2025

Apr 03, 2025

Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com

Apr 03, 2025

Mar 26, 2025

No room on the ARK? - Morningstar

Mar 26, 2025

Mar 25, 2025

5 Large Drug Stocks To Watch As Industry Recovers - Barchart

Mar 25, 2025

Mar 21, 2025

FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart

Mar 21, 2025

Mar 19, 2025

Novartis scraps use of diverse panels for hires in US - Reuters

Mar 19, 2025

Mar 14, 2025

Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart

Mar 14, 2025

Mar 13, 2025

Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.

Mar 13, 2025

Mar 12, 2025

Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.

Mar 12, 2025

Mar 07, 2025

Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart

Mar 07, 2025

Mar 07, 2025

Giovanni Caforio, M.D. - Novartis

Mar 07, 2025

Mar 05, 2025

Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily

Mar 05, 2025

Mar 04, 2025

META_TITLE_QUOTE - Yahoo Finance

Mar 04, 2025

Mar 04, 2025

Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily

Mar 04, 2025

Mar 03, 2025

Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance

Mar 03, 2025

Feb 26, 2025

AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com

Feb 26, 2025

Feb 25, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Feb 25, 2025

Feb 21, 2025

NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com

Feb 21, 2025

Feb 18, 2025

NVS Quantitative Stock Analysis - Nasdaq

Feb 18, 2025

Feb 16, 2025

Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha

Feb 16, 2025

Feb 13, 2025

Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle

Feb 13, 2025

Feb 13, 2025

Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH - Barchart

Feb 13, 2025